Vitamin D is a potential treatment for the management of gastrointestinal mucositis.
Journal
Current opinion in supportive and palliative care
ISSN: 1751-4266
Titre abrégé: Curr Opin Support Palliat Care
Pays: United States
ID NLM: 101297402
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
31
7
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
ppublish
Résumé
Gastrointestinal mucositis (GM) is a severe side effect of cancer treatments, negatively impacting the patient's quality of life, and has limited treatment. GM consists of complex biological processes involving apoptosis and inflammation, leading to damage and ulceration of the gastrointestinal system. Recently, vitamin D has been shown to have multiple roles in the gut, including immunomodulation, epithelial barrier regulation and microbiome regulation. Hence, this review aims to put forth vitamin D as a potential therapeutic due to its protective role in the intestine. Recent studies have shown that vitamin D can reduce intestinal inflammation by reducing NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation. Vitamin D also targets and maintains the intestinal epithelial barrier via the tight junction protein expression and the inhibition of microbiome translocation. Significant evidence also suggests that vitamin D exerts multiple therapeutic effects through binding to vitamin D receptors (VDRs), and the downregulation of VDR has been associated with the severity of the disease. Additionally, vitamin D deficiency is reported in cancer patients. There is a dire need for effective treatment for GM, and recent animal and human studies show that vitamin D may be a potential therapy to prevent or treat GM.
Identifiants
pubmed: 37276064
doi: 10.1097/SPC.0000000000000651
pii: 01263393-202309000-00019
doi:
Substances chimiques
Vitamin D
1406-16-2
Receptors, Calcitriol
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-252Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cinausero M, Aprile G, Ermacora P, et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front Pharmacol 2017; 8:354.
Dahlgren D, Sjöblom M, Hellström PM, et al. Chemotherapeutics-induced intestinal mucositis: pathophysiology and potential treatment strategies. Front Pharmacol 2021; 12:681417.
Sougiannis AT, VanderVeen BN, Davis JM, et al. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol 2021; 320:G712–G719.
Batista VL, da Silva TF, de Jesus LCL, et al. Probiotics, prebiotics, synbiotics, and paraprobiotics as a therapeutic alternative for intestinal mucositis. Front Microbiol 2020; 11:544490.
Stringer AM, Gibson RJ, Bowen JM, et al. Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007; 5:256–267.
Van Sebille YZA, Stansborough R, Wardill HR, et al. Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr Oncol Rep 2015; 17:1–8.
Huang FS, Kemp CJ, Williams JL, et al. Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury. Am J Physiol Gastrointest Liver Physiol 2002; 282:432–442.
Ali J, Khan AU, Shah FA, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci 2019; 239:116888.
Yilmaz E, Azizoglu ZB, Aslan K, et al. Therapeutic effects of vitamin D and IL-22 on methotrexate-induced mucositis in mice. Anticancer Drugs 2022; 33:11–18.
Ceylanli D, Şehirli AÖ, Gençosman S, et al. Protective effects of alpha-lipoic acid against 5-fluorouracil-induced gastrointestinal mucositis in rats. Antioxidants (Basel) 2022; 11 1930.
Karaman Ş, Karaçay Ö, Dizdar Y. Evaluation of DNA versus collagen perception in scientific articles examining cancer and radiation therapy: implication for collagen-based approaches. Eur Res J 2023; 9:22–28.
Sun J, Zhang YG. Vitamin D receptor influences intestinal barriers in health and disease. Cells 2022; 11:1129.
Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277–284.
Guo Y, Li X, Geng C, et al. Vitamin D receptor involves in the protection of intestinal epithelial barrier function via upregulating SLC26A3. J Steroid Biochem Mol Biol 2022; 227:106231.
Sultani M, Stringer AM, Bowen JM, et al. Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract 2012; 2012:490804.
Yazbeck R, Lindsay R, Abbott CA, et al. Combined effects of muricid extract and 5-fluorouracil on intestinal toxicity in rats. Evid Based Complement Alternat Med 2015; 2015:170858.
Chang CT, Ho TY, Lin H, et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS One 2012; 7:e31808.
Stringer AM, Al-Dasooqi N, Bowen JM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013; 21:1843–1852.
Nobre LMS, da Silva Lopes MH, Geraix J, et al. Paraprobiotic Enterococcus faecalis EC-12 prevents the development of irinotecan-induced intestinal mucositis in mice. Life Sci 2022; 296:120445.
Cheng WY, Wu C-Y, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut 2020; 69:1867–1876.
Zhao S, Wan D, Zhong Y, et al. 1α, 25-Dihydroxyvitamin D3 protects gastric mucosa epithelial cells against Helicobacter pylori -infected apoptosis through a vitamin D receptor-dependent c-Raf/MEK/ERK pathway. Pharm Biol 2022; 60:801–809.
Wei L, Wen XS, Xian CJ. Chemotherapy-induced intestinal microbiota dysbiosis impairs mucosal homeostasis by modulating toll-like receptor signaling pathways. Int J Mol Sci 2021; 22:9474.
Li W, Lin Y, Luo Y, et al. Vitamin D receptor protects against radiation-induced intestinal injury in mice via inhibition of intestinal crypt stem/progenitor cell apoptosis. Nutrients 2021; 13:2910.
Ong Z, Gibson RJ, Bowen JM, et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010; 5:22.
Hassanshahi M, Anderson PH, Sylvester CL, et al. Current evidence for vitamin D in intestinal function and disease. Exp Biol Med 2019; 244:1040–1052.
Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020; 74:1498–1513.
Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004; 89-90:611–614.
Anderson PH, May BK, Morris HA. Vitamin D metabolism: new concepts and clinical implications. Clin Biochem Rev 2003; 24:13–26.
Morris HA. Vitamin D: a hormone for all seasons – how much is enough? Clin Biochem Rev 2005; 26:21–32.
Sluyter JD, Manson JE, Scragg R. Vitamin D and clinical cancer outcomes: a review of meta-analyses. JBMR Plus 2021; 5:e10420.
Chandler PD, Chen WY, Ajala ON, et al. Effect of vitamin D3 supplements on development of advanced cancer: a secondary analysis of the VITAL randomized clinical trial. JAMA Netw Open 2020; 3:e2025850.
Holick CN, Stanford JL, Kwon EM, et al. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:1990–1999.
Jacobs ET, Van Pelt C, Forster RE, et al. CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res 2013; 73:2563–2573.
Vidigal VM, Silva TD, de Oliveira J, et al. Genetic polymorphisms of vitamin D receptor (VDR), CYP27B1 and CYP24A1 genes and the risk of colorectal cancer. Int J Biol Markers 2017; 32:e224–e230.
Voutsadakis IA. Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer. Mol Biol Rep 2020; 47:9821–9830.
Charehbili A, Hamdy NAT, Smit VTHBM, et al. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: data from the NEOZOTAC trial (BOOG 10-01). Breast 2015; 25:69–74.
Fakih MG, Trump DL, Johnson CS, et al. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis 2008; 24:219–224.
Lin Y, Xia P, Cao F, et al. Protective effects of activated vitamin D receptor on radiation-induced intestinal injury. J Cell Mol Med 2023; 27:246–258.
Arshad T, Mansur F, Palek R, et al. A double edged sword role of interleukin-22 in wound healing and tissue regeneration. Front Immunol 2020; 11:2148.
Miljković Đ, Jevtić B, Stojanović I, et al. ILC3, a central innate immune component of the gut-brain axis in multiple sclerosis. Front Immunol 2021; 12:657622.
Abdelmalak MFL, Abdelrahim DS, George Michael TMA, et al. Vitamin D and lactoferrin attenuate stress-induced colitis in Wistar rats via enhancing AMPK expression with inhibiting mTOR-STAT3 signaling and modulating autophagy. Cell Biochem Funct 2023; 41:211–222.
Zou Z, Tao T, Li H, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 2020; 10:31.
Yeung CY, Chiang Chiau JS, Cheng ML, et al. Effects of vitamin D-deficient diet on intestinal epithelial integrity and zonulin expression in a C57BL/6 mouse model. Front Med 2021; 8:649818.
Chen Z, Huang D, Yongyut P, et al. Vitamin D3 deficiency induced intestinal inflammatory response of turbot through nuclear factor-κB/inflammasome pathway, accompanied by the mutually exclusive apoptosis and autophagy. Front Immunol 2022; 13:986593.
Kanarek N, Grivennikov SI, Leshets M, et al. Critical role for IL-1β in DNA damage-induced mucositis. Proc Natl Acad Sci USA 2014; 111:E702–E711.
Cil O, Anderson MO, de Souza Goncalves L, et al. Small molecule inhibitors of intestinal epithelial anion exchanger SLC26A3 (DRA) with a luminal, extracellular site of action. Eur J Med Chem 2023; 249:115149.
Kumar A, Priyamvada S, Ge Y, et al. A novel role of SLC26A3 in the maintenance of intestinal epithelial barrier integrity. Gastroenterology 2021; 160:1240–1255.e3.
Liu X, Wang S, Jin S, et al. Vitamin D(3) attenuates cisplatin-induced intestinal injury by inhibiting ferroptosis, oxidative stress, and ROS-mediated excessive mitochondrial fission. Food Funct 2022; 13:10210–10224.
Vermandere K, Bostick RM, Tran HQ, et al. Effects of supplemental calcium and vitamin D on circulating biomarkers of gut barrier function in patients with colon adenoma: a randomized clinical trial. Cancer Prev Res (Phila) 2021; 14:393–402.
Bakr IS, Zaki AM, El-Moslemany RM, et al. Vitamin D oral gel for prevention of radiation-induced oral mucositis: a randomized clinical trial. Oral Dis 2021; 27:1197–1204.
Malaguarnera L. Vitamin D and microbiota: two sides of the same coin in the immunomodulatory aspects. Int Immunopharmacol 2020; 79:106112.
Hussein HM, Elyamany MF, Rashed LA, et al. Vitamin D mitigates diabetes-associated metabolic and cognitive dysfunction by modulating gut microbiota and colonic cannabinoid receptor 1. Eur J Pharm Sci 2022; 170:106105.